Fig 4.
Response of patient Cr3 with metastatic MET-amplified gastroesophageal cancer to the MET inhibitor crizotinib. (A) Pretreatment image and (B) partial response after two cycles of crizotinib (250 mg twice daily for a total of 8 weeks).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.